Today, a Director at Haemonetics Corp (HAE), Ronald Gelbman, sold shares of HAE for $446K.
Following Ronald Gelbman’s last HAE Sell transaction on December 14, 2016, the stock climbed by 61.2%. In addition to Ronald Gelbman, one other HAE executive reported Sell trades in the last month.
See today’s analyst top recommended stocks >>
Based on Haemonetics Corp’s latest earnings report for the quarter ending September 30, the company posted quarterly revenue of $242 million and quarterly net profit of $18.73 million. In comparison, last year the company earned revenue of $225 million and had a net profit of $20.1 million. HAE’s market cap is $5.24B and the company has a P/E ratio of 252.11. Currently, Haemonetics Corp has an average volume of 327.9K.
Based on 3 analyst ratings, the analyst consensus is Strong Buy with an average price target of $129.00, reflecting a 27.4% upside.
The insider sentiment on Haemonetics Corp has been negative according to 43 insider trades in the past three months. This sentiment is lower than the average sentiment of company insiders in this sector.
Company insider trades’ information is brought to you by the DailyInsider, a proprietary algorithm that analyzes insider trading activity to detect the most attractive trading opportunities. To subscribe to the DailyInsider visit this page.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Haemonetics Corp. is a healthcare company, which engages in the development and distribution of hematology products and solutions. It operates through the following geographical segments: Japan, EMEA (Europe, the Middle East, and Africa), North America Plasma, and All Other.
